Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFa used for the treatment of IBD: Results from the VERNE study

Background: Anti-TNF alpha represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. Aims: To assess the...

Descripción completa

Detalles Bibliográficos
Autores: Bastida, G, Marin-Jimenez, I, Fores, A, Garcia-Planella, E, Arguelles-Arias, F, Tagarro, I, Fernandez-Nistal, A, Montoto, C, Aparicio, J, Aguas, M, Santos-Fernandez, J, Bosca-Watts, M M, Ferreiro-Iglesias, R, Merino, O, Aldeguer, X, Cortes, X, Sicilia, B, Mesonero, F, Barreiro-de Acosta, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p16056
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/16056
Access Level:acceso abierto
Palabra clave:Anti-TNF alpha
Inflammatory bowel disease
Treatment discontinuation
Treatment intensification
Descripción
Sumario:Background: Anti-TNF alpha represent one of the main treatment approaches for the management of inflammatory bowel diseases (IBD). Therefore,the evaluation of their treatment patterns over time provides valuable insights about the clinical value of therapies and associated costs. Aims: To assess the treatment patterns with the first anti-TNF alpha in IBD. Methods: Retrospective, observational study. Results: 310 IBD patients were analyzed along a 5-year follow-up period. 56.2% of Crohn's disease (CD) patients started with adalimumab (ADA), while 43.8% started with infliximab (IFX). 12.9% of ulcerative colitis (UC) patients initiated with ADA, while 87.1% initiated with IFX. Treatment intensification was required in 28.9% of CD and 37.1% of UC patients. Median time to treatment intensification was shorter in UC than in CD (5.3 vs. 14.3 months; p = 0.028). Treatment discontinuation due to reasons other than remission were observed in 40.7% of CD and 40.5% of UC patients, although, in UC patients there was a trend to lower discontinuation rates with IFX (36.6%) than with ADA (66.7%). Loss of response accounted for approximately one-third of discontinuations, in both CD and UC. Conclusions: Around one-third of IBD biologic-naive patients treated with an anti-TNF alpha required treatment intensification (earlier in UC) and around 40% discontinued the anti-TNF alpha due to inappropriate disease control. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.

Similares en LA Referencia